Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image of an oncologist reviewing head and neck cancer scans in a modern clinical setting, reflecting Fulgent Genetics’ FID-007 Phase 2 data and the growing search for new post-PD-1 treatment options in recurrent or metastatic head and neck cancer.
Pharma & Biotech

Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026

Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.

Read More
Pharma & Biotech

Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens

Minghui and Qilu’s MHB088C data show durable disease control in mCRPC. Find out why the B7-H3 ADC still faces key clinical tests.

Read More
Representative image of a medical aesthetics consultation, reflecting Aphranel MagiCCrystal CaHA Filler’s EU MDR certification and the growing role of regenerative injectable treatments in Europe’s premium dermal filler market.
Medical Devices & Diagnostics

Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers

Aphranel’s CaHA filler has secured EU MDR certification. Find out what this means for regenerative aesthetics and Europe’s filler market.

Read More
Representative image of liver cancer research and CAR-T therapy development, reflecting growing industry interest in Oricell’s Ori-C101 data for late-line hepatocellular carcinoma.
Pharma & Biotech

Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight

Find out how Oricell’s Ori-C101 CAR-T data could reshape expectations for late-line liver cancer treatment after ASCO 2026.

Read More
Representative image showing a biotech licensing discussion around long-acting GLP-2 therapy, reflecting Lilly and Hanmi Pharm’s sonefpeglutide deal for short bowel syndrome treatment.
Pharma & Biotech

Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?

Read why Lilly’s Hanmi sonefpeglutide deal could reshape long-acting GLP-2 therapy for short bowel syndrome.

Read More
Representative image: Genentech’s obesity drug data update at ADA 2026 underscores rising interest in enicepatide, petrelintide and next-generation weight management therapies.
Pharma & Biotech

Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?

Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.

Read More
Representative image: A clinician reviews lung cancer imaging as ivonescimab survival data from the HARMONi-6 study raise fresh questions about the future of first-line squamous non-small cell lung cancer treatment.
Pharma & Biotech

Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?

Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.

Read More
Representative image showing AI-driven oncology research and cancer data analysis, reflecting Tempus AI’s Lens expansion into agentic AI tools for precision medicine and biopharma drug development.
Medical Devices & Diagnostics

Why Tempus AI’s Lens upgrade matters for precision oncology drug development

Tempus AI expands Lens with agentic AI for oncology drug development. Find out how it could reshape trials, evidence generation and biopharma R&D.

Read More
Representative image of an oncology researcher reviewing colorectal cancer scan data, reflecting Pfizer’s Braftovi regimen update in BRAF V600E-mutant metastatic colorectal cancer.
Pharma & Biotech

Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?

Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.

Read More
Representative image: Rare liver disease research is gaining fresh attention as Mirum Pharmaceuticals reports new EASL 2026 data on volixibat, brelovitug, and LIVMARLI.
Pharma & Biotech

Why clinicians and investors are watching Mirum Pharmaceuticals after its EASL 2026 update

Find out how Mirum Pharmaceuticals’ EASL 2026 data could reshape rare liver disease treatment and investor sentiment.

Read More